COEP News and Press, Coeptis Therapeutics Inc From 10/11/23

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology PR Newswire Coeptis now has exclusive rights to SNAP-CAR NK and SNAP-CAR T-Cell technology platforms WEXFORD, Pa. , Oct. 11, 2023 /PRNewswi...

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies PR Newswire WEXFORD, Pa. , Oct. 9, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopha...

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting PR Newswire Poster to be presented by research team from University of Pittsburgh , led by Jason Lohmueller , Ph.D., As...

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa PR Newswire WEXFORD, Pa. , Sept. 27, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASD...

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection PR Newswire DVX201, a first-ever allogeneic, cord-blood derived, natural killer (NK) cell therapy, ha...

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment PR Newswire Grants totaling approximately $3.5 million will support Deverra's CAR-NK and engin...

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer PR Newswire Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD,...

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics PR Newswire Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acut...

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic PR Newswire 513(g) request will help initiate dialogue with FDA and guide regulatory pathway WEXFORD, Pa. , Aug. 1, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings,...

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering PR Newswire WEXFORD, Pa. , June 16, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the "Company"), a biopharmaceutical company devel...